Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neurizon Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
Fundie Merchant Group picks four biotech stocks that could rip as sector hits rude health again
News
Closing Bell: Material gains for the ASX on Friday while a good week at work sees Tech Sector gain 7.5pc
Health & Biotech
FDA shows the way for accelerated approval of PharmAust’s monepantel in MND
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
Check Up: Aussie biotech Avarax on the verge of peanut allergy cure; and recent ASX health winners
News
Closing Bell: Local markets in a sulk for the cut that won’t come
Health & Biotech
PharmAust extension study begins as analysis shows MND/ALS drug ‘defied the odds’
News
ASX January winners: The best 50 stocks as ASX S&P reaches record high
Health & Biotech
ASX Health Winners January: ‘Invest in business not science’, as SHG and PAA top winners list
News
In Case You Missed It: Project expansions, mineral resources and boardroom appointments ahoy!
Health & Biotech
PharmAust gets ethics committee green light for open-label MND extension study
News
Market Highlights: ‘They could cut rates 15 times’… and 5 ASX small caps to watch
News
In Case You Missed It: Key approvals for resource plays and Aroa looks to improve mastectomy surgery
Health & Biotech
ASX Health Stocks: Starpharma says Viraleze reduces viral load in nose, effective in Covid-19
Health & Biotech
FDA offers PharmAust clear guidance for orphan drug designation approval
News
Rise and Shine: Everything you need to know before the ASX opens
News
